IOL type increases capsular block risk

Article

The incidence of capsular block syndrome (CBS), although rare, can be increased by design features of lenses implanted during cataract surgery, according to a study published in the March 2008 issue of the Journal of Cataract & Refractive Surgery.

The incidence of capsular block syndrome (CBS), although rare, can be increased by design features of lenses implanted during cataract surgery, according to a study published in the March 2008 issue of the Journal of Cataract & Refractive Surgery.

Hong Kyun Kim, MD and Jae Pil Shin, MD, PhD of the Department of Ophthalmology, Kyungpook National University, Daegu, Republic of Korea reviewed 990 patients (1100 eyes) implanted with posterior chamber intraocular lenses (PC IOLs) following cataract surgery in the period January 2003–June 2006.

The incidence of postoperative CBS (which was classified as noncellular, inflammatory or fibrotic) was 0.73% (n=8). Statistically significant risk factors for CBS development were identified as longer axial length (AL; odds ratio, 5.75) and the implantation of a four-haptic PC IOL (Akreos Adapt, Bausch & Lomb; odds ratio, 7.388).

The researchers concluded that AL and PC IOL design features could increase the likelihood of postoperative CBS development.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.